β‐Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis
- 26 January 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 67 (3) , 955-971
Abstract
Cholestatic liver diseases result from impaired bile flow and are characterized by inflammation, atypical ductular proliferation, and fibrosis. The Wnt/β‐catenin pathway plays a role in bile duct development, yet its role in cholestatic injury remains indeterminate. Liver‐specific β‐catenin knockout mice and wild‐type littermates were subjected to cholestatic injury through bile duct ligation or short‐term exposure to 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine diet. Intriguingly, knockout mice exhibit a dramatic protection from liver injury, fibrosis, and atypical ductular proliferation, which coincides with significantly decreased total hepatic bile acids (BAs). This led to the discovery of a role for β‐catenin in regulating BA synthesis and transport through regulation of farnesoid X receptor (FXR) activation. We show that β‐catenin functions as both an inhibitor of nuclear translocation and a nuclear corepressor through formation of a physical complex with FXR. Loss of β‐catenin expedited FXR nuclear localization and FXR/retinoic X receptor alpha association, culminating in small heterodimer protein promoter occupancy and activation in response to BA or FXR agonist. Conversely, accumulation of β‐catenin sequesters FXR, thus inhibiting its activation. Finally, exogenous suppression of β‐catenin expression during cholestatic injury reduces β‐catenin/FXR complex activation of FXR to decrease total BA and alleviate hepatic injury.Conclusion:We have identified an FXR/β‐catenin interaction whose modulation through β‐catenin suppression promotes FXR activation and decreases hepatic BAs, which may provide unique therapeutic opportunities in cholestatic liver diseases. (Hepatology2018;67:955–971)Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health (1R01DK62277, 1R01DK100287, 1R01DK103775)
This publication has 42 references indexed in Scilit:
- Pathogenesis of primary sclerosing cholangitisBest Practice & Research Clinical Gastroenterology, 2011
- Role of Wnt/β-catenin signaling in liver metabolism and cancerThe International Journal of Biochemistry & Cell Biology, 2011
- Liver-Specific β-Catenin Knockout Mice Have Bile Canalicular Abnormalities, Bile Secretory Defect, and Intrahepatic CholestasisHepatology, 2010
- Liver-Specific β-Catenin Knockout Mice Exhibit Defective Bile Acid and Cholesterol Homeostasis and Increased Susceptibility to Diet-Induced SteatohepatitisThe American Journal of Pathology, 2010
- Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasisHepatology, 2008
- Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutationsThe Journal of Pathology, 2007
- Benefit of farnesoid X receptor inhibition in obstructive cholestasisProceedings of the National Academy of Sciences, 2006
- Liver‐specific loss of β‐catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice†‡Hepatology, 2006
- Hepatic levels of bile acids in end-stage chronic cholestatic liver diseaseClinica Chimica Acta, 1996
- Heterogeneous expression of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase genes in the rat liver lobulus.Journal of Clinical Investigation, 1995